Physician profile
Richard Domsky
NPI 1760589824
$3,266.29
in general payments reported to CMS, 2019-2025
38 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $288 · 2021: $563 · 2022: $287 · 2023: $499 · 2024: $597 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,485.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $636.70 | 2021-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $513.86 | 2019-2025 | Relistor |
| Abbvie INC. | $354.59 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Abbott Laboratories | $278.23 | 2019-2024 | Proclaim |
| Scilex Pharmaceuticals INC. | $229.76 | 2019-2025 | Ztlido |
| Boston Scientific Corporation | $159.04 | 2020-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Biodelivery Sciences International, INC. | $136.56 | 2019-2021 | |
| Nevro Corp. | $100.42 | 2019-2020 | |
| Pfizer INC. | $94.01 | 2019-2024 | |
| Mdd US Operations, LLC | $80.06 | 2019 | |
| Si-Bone, INC. | $61.69 | 2019-2023 | |
| Zimmer Biomet Holdings, INC. | $48.25 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Vertex Pharmaceuticals Incorporated | $35.75 | 2024-2025 | |
| Daiichi Sankyo INC. | $35.58 | 2019 | |
| Valinor Pharma, LLC | $32.81 | 2024 | Movantik |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $31.12 | 2025 | Senza |
| Baudax Bio INC. | $28.63 | 2020 | |
| Ibsa Pharma INC. | $27.62 | 2022-2023 | Tirosint, Licart |
| Pacira Therapeutics, INC. | $27.24 | 2019 | |
| Horizon Therapeutics Plc | $27.16 | 2021 | |
| Redhill Biopharma INC. | $26.55 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.26 | 2020-2021 | |
| Tersera Therapeutics LLC | $24.60 | 2019 | |
| Zyla Life Sciences, INC. | $23.01 | 2019-2020 | |
| Stimwave Technologies Incorporated | $20.03 | 2019 | |
| Biotronik Nro, INC. | $19.60 | 2025 | Prospera |
| Azurity Pharmaceuticals, INC. | $18.31 | 2025 | Horizant |
| Medtronic, INC. | $17.72 | 2025 | Intellis Adaptivestim |
| Vertos Medical, INC. | $17.58 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.97 | 2022 | |
| Foundation Fusion Solutions, LLC | $16.97 | 2025 | |
| Painteq LLC | $16.82 | 2024 | Painteq |
| Amgen INC. | $15.75 | 2019 | |
| Virtus Pharmaceuticals LLC | $15.34 | 2025 | Levorphanol Tartrate |
| Sentynl Therapeutics, INC. | $14.15 | 2019 | |
| Medtronic USA, INC. | $13.35 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.26 | 2021 | |
| Lilly USA, LLC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Domsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.